Bayer's Faith In Pharma Pipeline Paying Off

Positive News For Nubeqa and Kerendia

The German major has presented the latest developments in the ongoing transformation of its pharmaceuticals business, starting with the prostate cancer therapy Nubeqa which Bayer believes will be a €3bn drug, way up on its earlier estimate of €1bn.

Bayer cross
• Source: Bayer

Observers concerned about the prospects for Bayer AG’s pharmaceutical operations once the big-selling heart drug Xarelto and blockbuster eye therapy Eylea lose patent protection will have been enthused by good news on Nubeqa and Kerendia, its two key growth-drivers for the rest of this decade and beyond.

More from Strategy

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 

Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.

Almirall CEO Sounds Alarm Over Europe’s Reduced Competitiveness

 
• By 

The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.

Can New US FDA Commissioner Makary Calm Agency During Turbulent Times?

 

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By 

Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.

More from Business

Can New US FDA Commissioner Makary Calm Agency During Turbulent Times?

 

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By 

Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.